focus -WSS

focus

author：focus 2025-09-27 21:54:39 - browse：3128

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： SCOTUS questions limit to govt efforts to fight misinformation

entertainment

WSS

Orchard's therapy for neuron disease in children wins FDA approval

House panel takes first step toward fixing drug shortages

White House Covid adviser calls on docs to combat misinformation

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

SCOTUS questions limit to govt efforts to fight misinformation

House panel takes first step toward fixing drug shortages

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Nurses recount patients attacks

Walensky prepares to leave CDC — and Congress — behind

Neuroscience’s long legacy of racism

Bright Health sells Medicare Advantage business to Molina

Asbestos, a deadly carcinogen, banned by EPA

Apple is now the first public company to be valued at $3 trillion

Transgender sports debate: Physicians say bans are health issue

Duchenne breakthrough therapy leaves behind pioneering families

Intermittent fasting comes with a heart risk? Not so fast

Wikipedia

Neurocrine congenital adrenal hyperplasia trial succeeds

SCOTUS questions limit to govt efforts to fight misinformation

Readout Newsletter: Bluebird, CVS, Contineum

Creating egg and sperm cells from stem cells raises ethical issues

Senate bill would ban some hospital facility fees

White House Covid adviser calls on docs to combat misinformation

entertainment

entertainment

Wikipedia

hotspot